Resolve M Therapeutics has emerged from stealth with a platform designed to identify, validate, and advance drug targets that activate the body’s natural “pro-resolution” pathways—aiming to restore immune balance in chronic inflammatory and autoimmune disorders without broadly suppressing the immune system.
The Cambridge, Massachusetts-based biotech was formed through a strategic collaboration between Johnson & Johnson, via its corporate venture capital arm Johnson & Johnson Innovation – JJDC, and company-creation firm General Inception. The partners said the venture reflects a company-build approach intended to accelerate translation from early scientific insights to clinical proof of concept.
Resolve M’s platform originated in the lab of Professor Nir Hacohen at the Broad Institute. The company is focused on harnessing the pro-resolving potential of the MS1 (myeloid state 1) cell state, which is characterized by suppressive functions that can be induced or modulated for therapeutic purposes across a range of inflammatory conditions. The underlying thesis is that enhancing resolution-phase biology can restore tissues to homeostasis following infection or injury, offering a potentially safer long-term approach than therapies that broadly dampen immune function.
Resolve M and its backers positioned the effort as a next step beyond earlier attempts to therapeutically engage resolution biology, which have largely centered on resolving lipid mediators and have not met expectations in clinical settings. By combining the Broad-derived platform with JJDC’s early-stage company-building model and General Inception’s operational infrastructure, the group plans to pursue both in vivo and in vitro methods to drive pro-resolving cells, deepen mechanistic understanding of myeloid cell function, and advance candidates with translational biomarkers that can help validate hypotheses in patients and inform iterative development decisions.
KEY QUOTES:
“Our findings of a defined myeloid cell state with suppressive functions provides a platform for induction, or modulation, of immune cells and their functions for therapeutic purposes in diverse inflammatory conditions.”
Professor Nir Hacohen, Core Member, Broad Institute; Professor of Medicine, Harvard Medical School
“By targeting the body’s innate resolution mechanisms with translatable biomarkers, we can rapidly validate our approach in patients and make real-time adjustments. This integrated model, merging world-class science, purpose-built infrastructure, and deep operational expertise, allows us to shorten development timelines, accelerating our journey to deliver transformative treatments for patients with chronic inflammatory diseases.”
Venkat Reddy, CSO, General Inception
